Cite
HARVARD Citation
Rasco, D. et al. (n.d.). 300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma. European journal of cancer. 51 (3), pp. S53-S54. [Online].